PCSK9 Recombinant Proteins, Antibodies and LDLR Research Tools

PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) is a secreted liver-derived protein that plays a central role in cholesterol and lipoprotein homeostasis. PCSK9 binds the low-density lipoprotein receptor (LDLR) and redirects internalized receptor toward lysosomal degradation instead of recycling back to the hepatocyte surface. Reduced LDLR availability lowers hepatic clearance of circulating LDL cholesterol, linking PCSK9 activity directly to plasma LDL-C levels. Human genetic studies showing large effects of PCSK9 gain- and loss-of-function variants on LDL-C and cardiovascular risk provide unusually strong genetic validation of this target. PCSK9 remains important for antibody, RNA-based, gene-editing, and long-acting metabolic research.

DIMA BIOTECH provides recombinant human PCSK9 protein for PCSK9-LDLR interaction studies, ELISA, SPR/BLI, immunization, affinity characterization, and blocking-antibody screening. Monoclonal antibodies validated by ELISA and flow cytometry are available together with a broad panel of reference antibodies and biotinylated or PE-conjugated formats. These reagents support PCSK9 detection, candidate benchmarking, capture assays, and functional competition studies. Candidate neutralizing antibodies can be further evaluated using PCSK9-LDLR competition and cellular LDLR-recycling or surface-expression assays.